About Icon Plc (NASDAQ:ICLR)
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:ICLR
- CUSIP: N/A
- Web: www.iconplc.com
- Debt-to-Equity Ratio: 0.31%
- Current Ratio: 1.90%
- Quick Ratio: 1.90%
Sales & Book Value:
- Trailing P/E Ratio: 21.56
- Forward P/E Ratio: 21.88
- P/E Growth: 1.74
- Annual Sales: $1.66649 billion
- Price / Sales: 3.81
- Cash Flow: $6.28 per share
- Price / Cash: 18.66
- Book Value: $20.82 per share
- Price / Book: 5.63
- Trailing EPS: $5.16
- Net Income: $262.17 million
- Net Margins: 16.37%
- Return on Equity: 28.42%
- Return on Assets: 15.06%
- Employees: 12,500
- Outstanding Shares: 54,150,000
Frequently Asked Questions for Icon Plc (NASDAQ:ICLR)
What is Icon Plc's stock symbol?
Icon Plc trades on the NASDAQ under the ticker symbol "ICLR."
How were Icon Plc's earnings last quarter?
Icon Plc (NASDAQ:ICLR) released its earnings results on Thursday, October, 26th. The medical research company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.03. The medical research company had revenue of $440.30 million for the quarter, compared to analyst estimates of $438.09 million. Icon Plc had a return on equity of 28.42% and a net margin of 16.37%. The company's quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.19 earnings per share. View Icon Plc's Earnings History.
When will Icon Plc make its next earnings announcement?
What guidance has Icon Plc issued on next quarter's earnings?
Icon Plc issued an update on its FY17 earnings guidance on Thursday, October, 26th. The company provided earnings per share (EPS) guidance of $5.30-5.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.37. The company issued revenue guidance of $1.74-1.77 billion, compared to the consensus revenue estimate of $1.76 billion.
Where is Icon Plc's stock going? Where will Icon Plc's stock price be in 2017?
10 Wall Street analysts have issued 1-year price targets for Icon Plc's shares. Their forecasts range from $92.00 to $138.00. On average, they anticipate Icon Plc's share price to reach $120.30 in the next twelve months. View Analyst Ratings for Icon Plc.
Are investors shorting Icon Plc?
Icon Plc saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 812,161 shares, a decrease of 34.9% from the October 13th total of 1,247,526 shares. Based on an average daily trading volume, of 334,705 shares, the short-interest ratio is presently 2.4 days. Currently, 1.5% of the shares of the company are sold short.
Who are some of Icon Plc's key competitors?
Some companies that are related to Icon Plc include Seattle Genetics (SGEN), Alkermes plc (ALKS), Qiagen N.V. (QGEN), Nektar Therapeutics (NKTR), Exact Sciences Corporation (EXAS), Ionis Pharmaceuticals (IONS), Covance (CVD), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Anacor Pharmaceuticals (ANAC), INC Research Holdings (INCR), Puma Biotechnology (PBYI), FibroGen (FGEN), ACADIA Pharmaceuticals (ACAD) and Shire Viropharma (VPHM).
Who are Icon Plc's key executives?
Icon Plc's management team includes the folowing people:
- Ciaran Murray, Chairman of the Board (Age 53)
- Steve Cutler, Chief Executive Officer, Director (Age 54)
- Brendan Brennan, Chief Financial Officer (Age 36)
- Diarmaid Cunningham, Executive Vice President, General Counsel, Secretary (Age 40)
- Hugh Brady, Non-Executive Director (Age 57)
- John Climax, Non-Executive Director (Age 62)
- William W. Hall M.D., Ph.D., Non-Executive Director (Age 65)
- Ronan Lambe Ph.D., Non-Executive Director (Age 75)
- Eugene McCague, Non-Executive Director
Who owns Icon Plc stock?
Icon Plc's stock is owned by many different of institutional and retail investors. Top institutional investors include WCM Investment Management CA (7.47%),
EARNEST PARTNERS LLC
(4.90%), Earnest Partners LLC (4.85%), Wasatch Advisors Inc. (3.37%), Neuberger Berman Group LLC (2.37%) and Boston Partners (2.05%). View Institutional Ownership Trends for Icon Plc.
Who sold Icon Plc stock? Who is selling Icon Plc stock?
Icon Plc's stock was sold by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Macquarie Group Ltd., Earnest Partners LLC, Boston Partners, Janus Henderson Group PLC, Systematic Financial Management LP, Pax World Management LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Icon Plc.
Who bought Icon Plc stock? Who is buying Icon Plc stock?
Icon Plc's stock was acquired by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Ameriprise Financial Inc., Westfield Capital Management Co. LP, Victory Capital Management Inc., WCM Investment Management CA, Comgest Global Investors S.A.S., Tygh Capital Management Inc. and Chartwell Investment Partners LLC. View Insider Buying and Selling for Icon Plc.
How do I buy Icon Plc stock?
Shares of Icon Plc can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Icon Plc's stock price today?
One share of Icon Plc stock can currently be purchased for approximately $117.25.
How big of a company is Icon Plc?
Icon Plc has a market capitalization of $6.08398 billion and generates $1.66649 billion in revenue each year. The medical research company earns $262.17 million in net income (profit) each year or $5.16 on an earnings per share basis. Icon Plc employs 12,500 workers across the globe.
How can I contact Icon Plc?
Icon Plc's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.
MarketBeat Community Rating for Icon Plc (NASDAQ ICLR)MarketBeat's community ratings are surveys of what our community members think about Icon Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Icon Plc (NASDAQ:ICLR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 2 Hold Ratings, 7 Buy Ratings, 1 Strong Buy Rating|
|Consensus Rating:||Buy (Score: 2.90)|
|Consensus Price Target: ||$120.30 (2.60% upside)|
Consensus Price Target History for Icon Plc (NASDAQ:ICLR)
Analysts' Ratings History for Icon Plc (NASDAQ:ICLR)
(Data available from 11/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/13/2017||KeyCorp||Reiterated Rating||Overweight||$115.00 -> $125.00||N/A|
|10/29/2017||SunTrust Banks, Inc.||Reiterated Rating||Reduce -> Buy||$138.00||N/A|
|10/27/2017||Barclays PLC||Boost Price Target||Equal Weight -> Equal Weight||$108.00 -> $120.00||N/A|
|10/16/2017||Credit Suisse Group||Reiterated Rating||Outperform||$105.00 -> $120.00||N/A|
|10/12/2017||Robert W. Baird||Reiterated Rating||Buy||$123.00||N/A|
|10/9/2017||Jefferies Group LLC||Boost Price Target||Buy||$122.00 -> $132.00||N/A|
|9/11/2017||Bank of America Corporation||Initiated Coverage||Buy -> Buy||$128.00||Low|
|7/27/2017||Mizuho||Boost Price Target||Neutral -> Neutral||$104.00 -> $108.00||Low|
|7/7/2017||Goldman Sachs Group, Inc. (The)||Upgrade||Buy -> Conviction-Buy||$117.00||High|
|4/28/2017||Evercore ISI||Boost Price Target||Outperform||$91.50 -> $92.00||Low|
|10/20/2016||Avondale Partners||Upgrade||Underperform -> Market Perform||N/A|
Earnings History and Estimates Chart for Icon Plc (NASDAQ:ICLR)
Earnings History by Quarter for Icon Plc (NASDAQ ICLR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/26/2017||9/30/2017||$1.32||$1.35||$438.09 million||$440.30 million||View||N/A|
|7/27/2017||6/30/2017||$1.30||$1.31||$430.68 million||$431.00 million||View||N/A|
|4/27/2017||3/31/2017||$1.27||$1.29||$432.21 million||$432.00 million||View||N/A|
|2/16/2017||Q416||$1.26||$1.33||$440.78 million||$435.00 million||View||Listen|
|10/20/2016||Q316||$1.18||$1.19||$420.14 million||$420.20 million||View||Listen|
|7/26/2016||Q216||$1.14||$1.14||$409.97 million||$411.00 million||View||Listen|
|4/26/2016||Q116||$1.11||$1.12||$414.35 million||$400.50 million||View||Listen|
|2/23/2016||Q415||$1.10||$1.11||$409.42 million||$403.00 million||View||Listen|
|10/27/2015||Q315||$1.01||$1.02||$399.02 million||$394.70 million||View||Listen|
|7/28/2015||Q215||$0.90||$0.95||$402.15 million||$389.00 million||View||Listen|
|4/28/2015||Q115||$0.81||$0.90||$391.11 million||$388.00 million||View||N/A|
|2/25/2015||Q4||$0.76||$0.87||$391.37 million||$390.10 million||View||N/A|
|10/22/2014||Q314||$0.70||$0.79||$391.12 million||$388.00 million||View||Listen|
|7/30/2014||Q2||$0.58||$0.64||$376.89 million||$376.00 million||View||Listen|
|4/30/2014||Q1||$0.50||$0.57||$352.14 million||$350.00 million||View||Listen|
|2/20/2014||Q413||$0.45||$0.53||$339.86 million||$345.00 million||View||Listen|
|10/24/2013||Q313||$0.41||$0.45||$332.58 million||$339.80 million||View||Listen|
|7/25/2013||Q2 2013||$0.38||$0.43||$321.82 million||$334.20 million||View||Listen|
|4/25/2013||Q1 2013||$0.34||$0.36||$300.81 million||$317.00 million||View||Listen|
|2/19/2013||Q4 2012||$0.33||$0.34||$291.96 million||$300.00 million||View||Listen|
|11/1/2012||Q312||$0.27||$0.29||$282.67 million||$286.00 million||View||N/A|
Earnings Estimates for Icon Plc (NASDAQ:ICLR)
2017 EPS Consensus Estimate: $5.29
2018 EPS Consensus Estimate: $5.90
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Icon Plc (NASDAQ:ICLR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Icon Plc (NASDAQ ICLR)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Icon Plc (NASDAQ:ICLR)
Latest Headlines for Icon Plc (NASDAQ ICLR)
Icon Plc (NASDAQ ICLR) Chart for Saturday, November, 18, 2017